WO2019203747A3 - Combinaison pharmaceutique comprenant du raloxifène et au moins un agent antipsychotique - Google Patents

Combinaison pharmaceutique comprenant du raloxifène et au moins un agent antipsychotique Download PDF

Info

Publication number
WO2019203747A3
WO2019203747A3 PCT/TR2018/050776 TR2018050776W WO2019203747A3 WO 2019203747 A3 WO2019203747 A3 WO 2019203747A3 TR 2018050776 W TR2018050776 W TR 2018050776W WO 2019203747 A3 WO2019203747 A3 WO 2019203747A3
Authority
WO
WIPO (PCT)
Prior art keywords
raloxifene
pharmaceutical combination
antipsychotic agent
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050776
Other languages
English (en)
Other versions
WO2019203747A2 (fr
Inventor
Ali TÜRKYILMAZ
Gülay Yelken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2019203747A2 publication Critical patent/WO2019203747A2/fr
Publication of WO2019203747A3 publication Critical patent/WO2019203747A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique qui comprend du raloxifène ou un sel pharmaceutiquement acceptable de celui-ci et au moins un agent antipsychotique ou un sel pharmaceutiquement acceptable de celui-ci, la combinaison ayant au moins une phase de libération comprenant une libération immédiate ou une libération modifiée ou les deux.
PCT/TR2018/050776 2017-12-08 2018-12-07 Combinaison pharmaceutique comprenant du raloxifène et au moins un agent antipsychotique Ceased WO2019203747A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/19893A TR201719893A2 (tr) 2017-12-08 2017-12-08 Raloksifen Ve En Az Bir Antipsikotik Ajan İçeren Farmasötik Kombinasyon
TR2017/19893 2017-12-08

Publications (2)

Publication Number Publication Date
WO2019203747A2 WO2019203747A2 (fr) 2019-10-24
WO2019203747A3 true WO2019203747A3 (fr) 2020-01-09

Family

ID=67952642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050776 Ceased WO2019203747A2 (fr) 2017-12-08 2018-12-07 Combinaison pharmaceutique comprenant du raloxifène et au moins un agent antipsychotique

Country Status (2)

Country Link
TR (1) TR201719893A2 (fr)
WO (1) WO2019203747A2 (fr)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHODAIE-ARDAKANI, M. R. ET AL.: "A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia", ACTA MEDICA IRANICA, vol. 53, no. 6, 15 June 2015 (2015-06-15), pages 337 - 345, XP055670943 *
KULKARNI, J. ET AL.: "Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial", JAMA PSYCHIATRY, vol. 73, no. 9, 20 June 2016 (2016-06-20), pages 947 - 954, XP055670930, ISSN: 2168-622X, DOI: 10.1001/jamapsychiatry.2016.1383 *

Also Published As

Publication number Publication date
WO2019203747A2 (fr) 2019-10-24
TR201719893A2 (tr) 2019-06-21

Similar Documents

Publication Publication Date Title
MY197700A (en) Compounds useful for inhibiting cdk7
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
EP3423112A4 (fr) Conjugués de type inhibiteur de hsp90-médicament
PH12019501076A1 (en) Pharmaceutical formulations
MX2017016802A (es) Formulaciones farmaceuticas.
PH12016502246A1 (en) Carboxamide derivatives
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
EP3672598A4 (fr) Compositions pharmaceutiques oculaires
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
TR201715231A2 (tr) Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon
EP4062938A4 (fr) Association médicamenteuse
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
WO2019209217A3 (fr) Formulations à libération modifiée de flurbiprofène
WO2019203747A3 (fr) Combinaison pharmaceutique comprenant du raloxifène et au moins un agent antipsychotique
WO2019098572A3 (fr) Composition pharmaceutique pour soulager la fibrose hépatique induite par le virus de l'hépatite
WO2019203748A3 (fr) Combinaison comprenant du raloxifène et au moins un agent antipsychotique
WO2019190427A3 (fr) Combinaison à libération immédiate comprenant du raloxifène et au moins un agent anti-psychotique
IN2014MU00043A (fr)
WO2019221684A3 (fr) Formulation de comprimé bicouche de fésotérodine
WO2020018053A3 (fr) Comprimé comprenant du dasatinib
SG11202006539RA (en) Cytocidal agent
WO2019203746A3 (fr) Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole
WO2019209208A3 (fr) Compositions pharmaceutiques d'ivabradine à libération contrôlée

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18915405

Country of ref document: EP

Kind code of ref document: A2